

# Manu Shankar-Hari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4951466/publications.pdf>

Version: 2024-02-01

177  
papers

36,847  
citations

30047

54  
h-index

4223

174  
g-index

210  
all docs

210  
docs citations

210  
times ranked

42206  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular and molecular mechanisms of IMMunE dysfunction and Recovery from SEpsis-related critical illness in adults: An observational cohort study (IMMERSE) protocol paper. <i>Journal of the Intensive Care Society</i> , 2022, 23, 318-324.	1.1	5
2	ARDS subphenotypes: searching for Rorschach among the roentgenograms?. <i>Thorax</i> , 2022, 77, 2-4.	2.7	2
3	Outcomes of critically ill COVID-19 patients managed in a high-volume severe respiratory failure and ECMO centre in the United Kingdom. <i>Journal of the Intensive Care Society</i> , 2022, 23, 233-236.	1.1	3
4	Association of cardiometabolic microRNAs with COVID-19 severity and mortality. <i>Cardiovascular Research</i> , 2022, 118, 461-474.	1.8	51
5	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	15.2	206
6	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. <i>EBioMedicine</i> , 2022, 76, 103856.	2.7	38
7	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2022, 141, 147-173.	1.8	22
8	Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. <i>Nature Medicine</i> , 2022, 28, 410-422.	15.2	392
9	Disrupted Peyer's Patch Microanatomy in COVID-19 Including Germinal Centre Atrophy Independent of Local Virus. <i>Frontiers in Immunology</i> , 2022, 13, 838328.	2.2	9
10	Towards a biological definition of ARDS: are treatable traits the solution?. <i>Intensive Care Medicine Experimental</i> , 2022, 10, 8.	0.9	32
11	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	13.7	174
12	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0228321.	1.8	5
13	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	3.8	83
14	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. <i>Trials</i> , 2022, 23, 401.	0.7	3
15	The Impact of Sample Size Misestimations on the Interpretation of ARDS Trials. <i>Chest</i> , 2022, 162, 1048-1062.	0.4	2
16	Redefining critical illness. <i>Nature Medicine</i> , 2022, 28, 1141-1148.	15.2	136
17	Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. <i>Critical Care</i> , 2022, 26, .	2.5	15
18	Protocol for a scoping review of sepsis epidemiology. <i>Systematic Reviews</i> , 2022, 11, .	2.5	2

#	ARTICLE	IF	CITATIONS
19	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. PLoS ONE, 2022, 17, e0270668.	1.1	16
20	Critical care outcomes, for the first 200 patients with confirmed COVID-19, in England, Wales and Northern Ireland: A report from the ICNARC Case Mix Programme. Journal of the Intensive Care Society, 2021, 22, 270-279.	1.1	7
21	Paediatric Inflammatory Multisystem Syndrome Temporally-Associated with SARS-CoV-2 Infection: An Overview. Intensive Care Medicine, 2021, 47, 90-93.	3.9	40
22	Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 543-552.	2.5	74
23	A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia. Molecular and Cellular Proteomics, 2021, 20, 100021.	2.5	5
24	Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 565-574.	2.5	117
25	Sepsis Subclasses: A Framework for Development and Interpretation*. Critical Care Medicine, 2021, 49, 748-759.	0.4	81
26	Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. European Respiratory Review, 2021, 30, 200317.	3.0	34
27	Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. Critical Care, 2021, 25, 106.	2.5	121
28	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	13.9	1,419
29	Utilising mass cytometry with CD45 barcoding and standardised leucocyte phenotyping for immune trajectory assessment in critically ill patients. British Journal of Anaesthesia, 2021, 126, e149-e152.	1.5	4
30	Changes in temperature management and outcome after out-of-hospital cardiac arrest in United Kingdom intensive care units following publication of the targeted temperature management trial. Resuscitation, 2021, 162, 304-311.	1.3	32
31	Degradation of the Endothelial Glycocalyx Contributes to Metabolic Acidosis in Children Following Cardiopulmonary Bypass Surgery. Pediatric Critical Care Medicine, 2021, 22, e571-e581.	0.2	7
32	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. Journal of Infectious Diseases, 2021, 224, 595-605.	1.9	20
33	Immunological Subpopulations Within Critically Ill COVID-19 Patients. Chest, 2021, 159, 1706-1708.	0.4	1
34	Delirium in COVID-19: can we make the unknowns knowns?. Intensive Care Medicine, 2021, 47, 1144-1147.	3.9	6
35	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, 2021, 54, 1276-1289.e6.	6.6	112
36	Initial setting of high-flow nasal oxygen post extubation based on mean inspiratory flow during a spontaneous breathing trial. Journal of Critical Care, 2021, 63, 40-44.	1.0	4

#	ARTICLE	IF	CITATIONS
37	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. <i>Lancet Respiratory Medicine</i> , 2021, 9, 622-642.	5.2	371
38	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. <i>Nature Communications</i> , 2021, 12, 3406.	5.8	122
39	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Medicine</i> , 2021, 47, 867-886.	3.9	65
40	Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-104.	0.9	11
41	Impact of differences in acute respiratory distress syndrome randomised controlled trial inclusion and exclusion criteria: systematic review and meta-analysis. <i>British Journal of Anaesthesia</i> , 2021, 127, 85-101.	1.5	13
42	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506.	2.2	58
43	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
44	Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. <i>BMJ</i> , The, 2021, 374, n1931.	3.0	217
45	Reflections on Critical Care's Past, Present, and Future. <i>Critical Care Medicine</i> , 2021, 49, 1855-1865.	0.4	13
46	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
47	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. <i>PLoS ONE</i> , 2021, 16, e0256813.	1.1	23
48	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1345-1347.	4.6	26
49	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021, 591, 92-98.	13.7	1,014
50	Prognostic Factors for 30-Day Mortality in Critically Ill Patients With Coronavirus Disease 2019: An Observational Cohort Study. <i>Critical Care Medicine</i> , 2021, 49, 102-111.	0.4	61
51	The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?. <i>Intensive Care Medicine</i> , 2021, 47, 1315-1318.	3.9	6
52	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
53	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
54	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e055435.	0.8	10

#	ARTICLE	IF	CITATIONS
55	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. <i>EClinicalMedicine</i> , 2021, 41, 101167.	3.2	22
56	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
57	The immunology of sepsis. <i>Immunity</i> , 2021, 54, 2450-2464.	6.6	263
58	Towards an ecological definition of sepsis: a viewpoint. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 63.	0.9	2
59	Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis?. <i>Intensive Care Medicine</i> , 2020, 46, 119-121.	3.9	10
60	Trials on oxygen supplementation in sepsis: better late than never. <i>Intensive Care Medicine</i> , 2020, 46, 116-118.	3.9	5
61	Translational Research in the Time of COVID-19 – Dissolving Boundaries. <i>PLoS Pathogens</i> , 2020, 16, e1008898.	2.1	7
62	COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. <i>Intensive Care Medicine</i> , 2020, 46, 2035-2047.	3.9	117
63	Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. <i>Critical Care</i> , 2020, 24, 449.	2.5	16
64	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 691.	0.7	62
65	International variation in the management of severe COVID-19 patients. <i>Critical Care</i> , 2020, 24, 486.	2.5	55
66	Physiological dead space ventilation, disease severity and outcome in ventilated patients with hypoxaemic respiratory failure due to coronavirus disease 2019. <i>Intensive Care Medicine</i> , 2020, 46, 2092-2093.	3.9	19
67	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020, 5, 1598-1607.	5.9	1,115
68	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1317.	3.8	671
69	A living WHO guideline on drugs for covid-19. <i>BMJ, The</i> , 2020, 370, m3379.	3.0	664
70	Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1209-1218.	5.2	174
71	Outcomes in mechanically ventilated patients with hypoxaemic respiratory failure caused by COVID-19. <i>British Journal of Anaesthesia</i> , 2020, 125, e480-e483.	1.5	13
72	A dynamic COVID-19 immune signature includes associations with poor prognosis. <i>Nature Medicine</i> , 2020, 26, 1623-1635.	15.2	765

#	ARTICLE	IF	CITATIONS
73	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. <i>Nature Medicine</i> , 2020, 26, 1701-1707.	15.2	315
74	Development, Validation, and Clinical Utility Assessment of a Prognostic Score for 1-Year Unplanned Rehospitalization or Death of Adult Sepsis Survivors. <i>JAMA Network Open</i> , 2020, 3, e2013580.	2.8	12
75	Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. <i>BMJ Open</i> , 2020, 10, e038847.	0.8	4
76	The interaction between arterial oxygenation and carbon dioxide and hospital mortality following out of hospital cardiac arrest: a cohort study. <i>Critical Care</i> , 2020, 24, 336.	2.5	18
77	Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. <i>Trials</i> , 2020, 21, 462.	0.7	24
78	Use of Hydrocortisone Based on Plasma Biomarkers in Patients with Septic Shock: Another One Bites the Dust?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 644-646.	2.5	1
79	Relationship between norepinephrine dose, tachycardia and outcome in septic shock: A multicentre evaluation. <i>Journal of Critical Care</i> , 2020, 57, 185-190.	1.0	30
80	Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. <i>Acta Neuropathologica</i> , 2020, 140, 397-400.	3.9	85
81	Lack of Clinical Benefit of Interferon $\hat{2}$ -1a Among Patients With Severe Acute Respiratory Distress Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 713.	3.8	5
82	Could stress ulcer prophylaxis increase mortality in high-acuity patients?. <i>Intensive Care Medicine</i> , 2020, 46, 793-795.	3.9	7
83	Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2020, 46, 619-636.	3.9	53
84	Demographic Shifts, Case Mix, Activity, and Outcome for Elderly Patients Admitted to Adult General ICUs in England, Wales, and Northern Ireland. <i>Critical Care Medicine</i> , 2020, 48, 466-474.	0.4	16
85	Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2897.	1.8	17
86	Maternal Risk Modeling in Critical Careâ€”Development of a Multivariable Risk Prediction Model for Death and Prolonged Intensive Care*. <i>Critical Care Medicine</i> , 2020, 48, 663-672.	0.4	7
87	Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , 2020, 115, 10-14.	0.4	14
88	Current Understanding of Leukocyte Phenotypic and Functional Modulation During Extracorporeal Membrane Oxygenation: A Narrative Review. <i>Frontiers in Immunology</i> , 2020, 11, 600684.	2.2	14
89	Rethinking animal models of sepsis â€œ working towards improved clinical translation whilst integrating the 3Rs. <i>Clinical Science</i> , 2020, 134, 1715-1734.	1.8	12
90	Is T Cell Exhaustion a Treatable Trait in Sepsis?. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2020, , 271-279.	0.1	1

#	ARTICLE	IF	CITATIONS
91	Focus on sepsis. <i>Intensive Care Medicine</i> , 2019, 45, 1459-1461.	3.9	10
92	Current gaps in sepsis immunology: new opportunities for translational research. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e422-e436.	4.6	205
93	Sepsis hysteria: excess hype and unrealistic expectations. <i>Lancet</i> , The, 2019, 394, 1513-1514.	6.3	60
94	A Comparison of Mortality From Sepsis in Brazil and England. <i>Critical Care Medicine</i> , 2019, 47, 76-84.	0.4	15
95	Risk Factors at Index Hospitalization Associated With Longer-term Mortality in Adult Sepsis Survivors. <i>JAMA Network Open</i> , 2019, 2, e194900.	2.8	63
96	Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. <i>Critical Care</i> , 2019, 23, 156.	2.5	27
97	Do Sepsis-3 Criteria Facilitate Earlier Recognition of Sepsis and Septic Shock? A Retrospective Cohort Study. <i>Shock</i> , 2019, 51, 306-311.	1.0	12
98	Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: infection and sepsis. <i>British Journal of Anaesthesia</i> , 2019, 122, 500-508.	1.5	34
99	Population enrichment for critical care trials: phenotypes and differential outcomes. <i>Current Opinion in Critical Care</i> , 2019, 25, 489-497.	1.6	40
100	Readmission Diagnoses After Pediatric Severe Sepsis Hospitalization*. <i>Critical Care Medicine</i> , 2019, 47, 583-590.	0.4	23
101	Lung Recruitability in Severe Acute Respiratory Distress Syndrome Requiring Extracorporeal Membrane Oxygenation. <i>Critical Care Medicine</i> , 2019, 47, 1177-1183.	0.4	29
102	Acute respiratory distress syndrome (ARDS) phenotyping. <i>Intensive Care Medicine</i> , 2019, 45, 516-519.	3.9	38
103	Estimating attributable fraction of mortality from sepsis to inform clinical trials. <i>Journal of Critical Care</i> , 2018, 45, 33-39.	1.0	29
104	In Pursuit of Precision Medicine in the Critically Ill. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2018, , 649-658.	0.1	5
105	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). <i>Intensive Care Medicine</i> , 2018, 44, 438-448.	3.9	96
106	Immunoglobulins and sepsis. <i>Intensive Care Medicine</i> , 2018, 44, 1923-1925.	3.9	15
107	Immune Activation in Sepsis. <i>Critical Care Clinics</i> , 2018, 34, 29-42.	1.0	59
108	Caring for Sepsis Patients: An Update. <i>Critical Care Clinics</i> , 2018, 34, xiii-xv.	1.0	0

#	ARTICLE	IF	CITATIONS
109	Acceptance and transfer to a regional severe respiratory failure and veno-venous extracorporeal membrane oxygenation (ECMO) service: predictors and outcomes. <i>Anaesthesia</i> , 2018, 73, 177-186.	1.8	19
110	Early PRediction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study. <i>Intensive Care Medicine</i> , 2018, 44, 1836-1848.	3.9	59
111	Lessons From ARDS for Non-ARDS Research. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1863.	3.8	10
112	Major surgery and the immune system: from pathophysiology to treatment. <i>Current Opinion in Critical Care</i> , 2018, 24, 588-593.	1.6	19
113	Race, Ethnicity, and Sepsis: Beyond Adjusted Odds Ratios*. <i>Critical Care Medicine</i> , 2018, 46, 1009-1010.	0.4	5
114	Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 691-698.	5.2	455
115	Relationship between Anaemia, Haemolysis, Inflammation and Haem Oxygenase-1 at Admission with Sepsis: a pilot study. <i>Scientific Reports</i> , 2018, 8, 11198.	1.6	26
116	qSOFA, Cue Confusion. <i>Annals of Internal Medicine</i> , 2018, 168, 293.	2.0	20
117	Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. <i>Critical Care</i> , 2018, 22, 95.	2.5	56
118	Corticosteroid therapy for sepsis: a clinical practice guideline. <i>BMJ: British Medical Journal</i> , 2018, 362, k3284.	2.4	76
119	Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. <i>Intensive Care Medicine</i> , 2018, 44, 627-635.	3.9	97
120	The intensive care medicine research agenda on septic shock. <i>Intensive Care Medicine</i> , 2017, 43, 1294-1305.	3.9	61
121	Activation-Associated Accelerated Apoptosis of Memory B Cells in Critically Ill Patients With Sepsis. <i>Critical Care Medicine</i> , 2017, 45, 875-882.	0.4	83
122	The use of enrichment to reduce statistically indeterminate or negative trials in critical care. <i>Anaesthesia</i> , 2017, 72, 560-565.	1.8	30
123	Protocolised early goal-directed therapy in patients with sepsis/septic shock does not result in improved survival compared with usual care with less invasive resuscitation strategies. <i>Evidence-Based Medicine</i> , 2017, 22, 223-223.	0.6	0
124	Septic shock resuscitation in the first hour. <i>Current Opinion in Critical Care</i> , 2017, 23, 561-566.	1.6	14
125	Just Because Things Are Not Different, Does Not Mean They Are the Same. <i>Critical Care Medicine</i> , 2017, 45, 1955-1957.	0.4	1
126	Divide and conquer: identifying acute respiratory distress syndrome subphenotypes. <i>Thorax</i> , 2017, 72, 867-869.	2.7	11



#	ARTICLE	IF	CITATIONS
127	Can Concurrent Abnormalities in Free Light Chains and Immunoglobulin Concentrations Identify a Target Population for Immunoglobulin Trials in Sepsis?. Critical Care Medicine, 2017, 45, 1829-1836.	0.4	19
128	Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. British Journal of Anaesthesia, 2017, 119, 626-636.	1.5	177
129	37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3). Critical Care, 2017, 21, .	2.5	7
130	How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis?. Critical Care, 2017, 21, 125.	2.5	8
131	Acute Respiratory Distress Syndrome Phenotypes and Identifying Treatable Traits. The Dawn of Personalized Medicine for ARDS. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 280-281.	2.5	20
132	Early PRediction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers. BMJ Open, 2016, 6, e011335.	0.8	5
133	Predictive value of cell-surface markers in infections in critically ill patients: protocol for an observational study (ImmuNe FailurE in Critical Therapy (INFECT) Study). BMJ Open, 2016, 6, e011326.	0.8	8
134	Differences in Impact of Definitional Elements on Mortality Precludes International Comparisons of Sepsis Epidemiology—A Cohort Study Illustrating the Need for Standardized Reporting*. Critical Care Medicine, 2016, 44, 2223-2230.	0.4	63
135	Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges. Current Infectious Disease Reports, 2016, 18, 37.	1.3	124
136	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2016, 316, 509.	3.8	456
137	Defining Septic Shock—Reply. JAMA - Journal of the American Medical Association, 2016, 316, 456.	3.8	4
138	Fatal cardiovascular instability secondary to hypercalcaemia and intracellular calcium deposition complicating T-cell leukaemia-lymphoma. JRSM Open, 2016, 7, 205427041560811.	0.2	2
139	Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies. Critical Care, 2016, 20, 101.	2.5	87
140	The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA - Journal of the American Medical Association, 2016, 315, 801.	3.8	16,554
141	Assessment of Clinical Criteria for Sepsis. JAMA - Journal of the American Medical Association, 2016, 315, 762.	3.8	2,727
142	Developing a New Definition and Assessing New Clinical Criteria for Septic Shock. JAMA - Journal of the American Medical Association, 2016, 315, 775.	3.8	1,622
143	Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections*. Critical Care Medicine, 2015, 43, 2283-2291.	0.4	159
144	An international survey of nutrition practices in adult patients receiving veno-venous ECMO. Intensive Care Medicine Experimental, 2015, 3, .	0.9	13

#	ARTICLE	IF	CITATIONS
145	IMPACT OF TRIALS ON CLINICAL PRACTICE: INTERVENTIONS IN SEPTIC SHOCK PATIENTS BETWEEN 2005 AND 2013. <i>Intensive Care Medicine Experimental</i> , 2015, 3, .	0.9	0
146	Activation-associated death of memory b cells in peripheral circulation in adults with sepsis. <i>Intensive Care Medicine Experimental</i> , 2015, 3, .	0.9	0
147	Does sepsis cause increased long-term mortality? a systematic review. <i>Intensive Care Medicine Experimental</i> , 2015, 3, .	0.9	0
148	Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2015, 41, 1393-1401.	3.9	57
149	Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses. <i>Medical Decision Making</i> , 2015, 35, 608-621.	1.2	16
150	Judging quality of current septic shock definitions and criteria. <i>Critical Care</i> , 2015, 19, 445.	2.5	20
151	Do we need a new definition of sepsis?. <i>Intensive Care Medicine</i> , 2015, 41, 909-911.	3.9	47
152	The diagnostic and prognostic significance of monitoring blood levels of immature neutrophils in patients with systemic inflammation. <i>Critical Care</i> , 2015, 19, 57.	2.5	94
153	International survey on the management of mechanical ventilation during ECMO in adults with severe respiratory failure. <i>Minerva Anestesiologica</i> , 2015, 81, 1170-83, 77 p following 1183.	0.6	29
154	The influence of statin exposure on inflammatory markers in patients with early bacterial infection: pilot prospective cohort study. <i>BMC Anesthesiology</i> , 2014, 14, 106.	0.7	5
155	Healthcare-associated bloodstream infections in critically ill patients: descriptive cross-sectional database study evaluating concordance with clinical site isolates. <i>Annals of Intensive Care</i> , 2014, 4, 34.	2.2	14
156	Redox State of Pentraxin 3 as a Novel Biomarker for Resolution of Inflammation and Survival in Sepsis. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2545-2557.	2.5	37
157	Long-term adherence to a 5 day antibiotic course guideline for treatment of intensive care unit (ICU)-associated Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1688-1694.	1.3	7
158	Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. <i>Critical Care</i> , 2014, 18, 649.	2.5	24
159	Quantitative Assessment of the Effects of Therapeutic Hypothermia on Early Repolarization in Idiopathic Ventricular Fibrillation Survivors. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 120-126.	2.1	8
160	How might a diagnostic microRNA signature be used to speed up the diagnosis of sepsis?. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 249-251.	1.5	7
161	P258Redox-state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis. <i>Cardiovascular Research</i> , 2014, 103, S46.3-S46.	1.8	0
162	Determinant-Based Classification of Acute Pancreatitis Severity. <i>Annals of Surgery</i> , 2012, 256, 875-880.	2.1	425

#	ARTICLE	IF	CITATIONS
163	Statin therapy in critical illness: an international survey of intensive care physicians' opinions, attitudes and practice. BMC Clinical Pharmacology, 2012, 12, 13.	2.5	3
164	An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.. Health Technology Assessment, 2012, 16, 1-186.	1.3	65
165	Prevalence of Gram-negative bacilli resistance in adult critically ill patients at admission screening. Critical Care, 2011, 15, .	2.5	0
166	Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Critical Care, 2011, 16, 206.	2.5	95
167	The critically ill patient: making the referral to intensive care. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, M154-M156.	0.2	1
168	The critically ill patient: identification and initial stabilization. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, M138-M140.	0.2	1
169	International standards for programmes of training in intensive care medicine in Europe. Intensive Care Medicine, 2011, 37, 385-393.	3.9	44
170	Utility of an antibiotic guideline in hospital-associated infections. Critical Care, 2010, 14, P51.	2.5	0
171	A life-threatening sore throat masquerading as swine flu. Lancet, The, 2010, 375, 524.	6.3	3
172	Neurogenic diabetes insipidus presenting in a patient with subacute liver failure: a case report. Journal of Medical Case Reports, 2010, 4, 232.	0.4	1
173	Activated protein C in severe acute pancreatitis without sepsis? Not just yet .... Critical Care, 2010, 14, 188.	2.5	14
174	The educational environment for training in intensive care medicine: structures, processes, outcomes and challenges in the European region. Intensive Care Medicine, 2009, 35, 1575-1583.	3.9	59
175	Continuous renal replacement therapy (CRRT) in patients with liver disease: Is circuit life different?. Journal of Hepatology, 2009, 51, 504-509.	1.8	60
176	Retropharyngeal abscess presenting with upper airway obstruction. Anaesthesia, 2003, 58, 714-715.	1.8	9
177	Albumin versus balanced crystalloid for resuscitation in the treatment of sepsis: A protocol for a randomised controlled feasibility study, 'ABC-Sepsis'. Journal of the Intensive Care Society, 0, , 175114372211036.	1.1	3